Key result
Continuation of anti-platelet therapy until coronary artery bypass grafting increased excessive postoperative bleeding compared to preoperative discontinuation, and preoperative point-of-care platelet function testing was a strong predictor of this bleeding risk.
Why the study?
Does point-of-care platelet function testing predict excessive bleeding and transfusion requirements in patients undergoing coronary artery bypass grafting?
Cohort (n=84)
Double-blind
No
Does point-of-care platelet function testing predict excessive bleeding and transfusion requirements in patients undergoing coronary artery bypass grafting?
Peri-operative point-of-care platelet function testing using the Multiplate device strongly predicts bleeding and transfusion requirements in CABG patients who remain on anti-platelet therapy until surgery.
Answers are grounded in this paper and cite their sources.
May support preoperative antiplatelet discontinuation before CABG; leaves open the utility of routine platelet function testing.
OBJECTIVE: OBJECTIVE platelet function assessment after cardiac surgery can predict postoperative blood loss, guide transfusion requirements and discriminate the need for surgical re-exploration. We conducted this study to assess the predictive value of point-of-care testing platelet function using the Multiplate® device. METHODS: Patients undergoing isolated coronary artery bypass grafting were prospectively recruited ( n = 84). Group A ( n = 42) patients were on anti-platelet therapy until surgery; patients in Group B ( n = 42) stopped anti-platelet treatment at least 5 days preoperatively. Multiplate® and thromboelastography (TEG) tests were performed in the perioperative period. Primary end-point was excessive bleeding (>2.5 ml/kg/h) within first 3 h postoperative. Secondary end-points included transfusion requirements, re-exploration rates, intensive care unit and in-hospital stays. RESULTS: Patients in Group A had excessive bleeding (59% vs. 33%, P = 0.02), higher re-exploration rates (14% vs. 0%, P < 0.01) and higher rate of blood (41% vs. 14%, P < 0.01) and platelet (14% vs. 2%, P = 0.05) transfusions. On multivariate analysis, preoperative platelet function testing was the most significant predictor of excessive bleeding (odds ratio [OR]: 2.3, P = 0.08), need for blood (OR: 5.5, P < 0.01) and platelet transfusion (OR: 15.1, P < 0.01). Postoperative "ASPI test" best predicted the need for transfusion (sensitivity - 0.86) and excessive blood loss (sensitivity - 0.81). TEG results did not correlate well with any of these outcome measures. CONCLUSIONS: Peri-operative platelet functional assessment with Multiplate® was the strongest predictor for bleeding and transfusion requirements in patients on anti-platelet therapy until the time of surgery.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2015) conducted a cohort in Coronary artery disease requiring coronary artery bypass grafting (n=84). Continuation of anti-platelet therapy until surgery vs. Discontinuation of anti-platelet therapy ≥5 days preoperatively was evaluated on Excessive bleeding (>2.5 ml/kg/h) within first 3 h postoperative (p=0.02). Continuation of anti-platelet therapy until coronary artery bypass grafting increased excessive postoperative bleeding compared to preoperative discontinuation, and preoperative point-of-care platelet function testing was a strong predictor of this bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: